| Literature DB >> 25374740 |
Saul Oswaldo Lugo Reyes1, Nizar Mahlaoui2, Carolina Prando3, Lizbeth Blancas Galicia1, Marjorie Hubeau4, Stéphane Blanche5, Capucine Picard6, Jean-Laurent Casanova7, Jacinta Bustamante8.
Abstract
Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by increased susceptibility to bacteria and fungi since early in life, caused by mutations in any of the five genes coding for protein subunits in NADPH oxidase. X-linked variant CGD can be missed during routine evaluation or present later in life due to hypomorphic mutations and a residual superoxide production. The case of a 10-month-old boy who died of pneumonia is reported. The isolation of Burkholderia cepacia from his lung, together with a marginally low nitroblue tetrazolium reduction assay (NBT), made us suspect and pursue the molecular diagnosis of CGD. A postmortem genetic analysis finally demonstrated CGD caused by a hypomorphic missense mutation with normal gp91 (phox) expression. In a patient being investigated for unusually severe or recurrent infection, a high index of suspicion of immunodeficiency must be maintained.Entities:
Year: 2013 PMID: 25374740 PMCID: PMC4207590 DOI: 10.1155/2013/323614
Source DB: PubMed Journal: Case Reports Immunol ISSN: 2090-6617
Figure 1NADPH oxidase activity evaluation in PMNs. (a) Superoxide generation was measured by assaying superoxide dismutase-inhibitable cytochrome-c reduction in PNMs after adding three doses of PMA (4, 40, and 400 ng/mL), for healthy controls (C+), CGD patient (C−), and our patient (P). (b) Histograms for the flow cytometric analysis of intracellular H2O2 production, using the fluorescent 123DHR probe in PMNs from a healthy control (C+), an X-linked CGD patient (C−), the proband (P), and the mother (H), before (NS) and after stimulation with PMA (4, 40, and 400 ng/mL). (c) PMNs from C+, C−, and P were left untreated or treated with TNF-α, IL-1β, and cytochalasin b and then stimulated with fMLF. The results shown are representative of two independent experiments.
Figure 2Expression of gp91 in a patient with the H338R CYBB mutation. Immunostaining of cytochrome b558 in EBV-B cells from a healthy control (C+), an X-linked CGD patient (C−), and the patient (P). Cell surface staining with mAb7D5 (an antibody specific for the extracellular epitope of gp91; solid lines); an isotype IgG1 (dotted lines) followed by staining with an Alexa Fluor 488 goat anti-mouse Ig secondary antibody. The results shown are representative of two independent experiments.